Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TSPO | P30536 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9739282 | 0.79 | HTT (0.57) | HTTMAPK10SMN1; SMN2MAPTNPC1 | |
| SCHEMBL27390233 | 0.79 | HTT (0.53) | HTTMAPK10SMN1; SMN2MAPTNPC1 | |
| SCHEMBL9714958 | 0.71 | SMN1; SMN2 (0.46) | HTTMAPK10SMN1; SMN2MAPTNPC1 | |
| SCHEMBL27390328 | 0.70 | ROCK2 (0.42) | HTTMAPK10SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4002523 | 0.70 | ALDH1A1 (0.56) | HTTSMN1; SMN2TSPOALDH1A1LMNA | |
| SCHEMBL8034982 | 0.70 | HTT (0.56) | HTTMAPK10SMN1; SMN2MAPTNPC1 | |
| SCHEMBL9714927 | 0.70 | RAB9A (0.44) | HTTMAPK10SMN1; SMN2RAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL9715094 | 0.69 | LMNA (0.53) | HTTMAPK10SMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL9714985 | 0.69 | ABL1 (0.43) | HTTMAPK10SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL9714945 | 0.67 | HSD17B10 (0.46) | HTTMAPK10SMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458161-B1 | TSPO ligands for cancer imaging and treatment | VANDERBLIT UNIVERSITY (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2035421-B1 | 2-Arylpyrazolo[l,5-alpha]pyrimidin-3-yl acetamide derivatives as ligands for translocator protein (18 kDa) | UNIV SYDNEY (AU) | 2014-07-02 | — | — | EP | disclosed |
| US-20120189548-A1 | 2-ARYLPYRAZOLO[L,5-ALPHA]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | THE UNIVERSITY OF SYDNEY (AU) | 2012-07-26 | — | — | US | disclosed |
| US-20120189548-A1 | 2-ARYLPYRAZOLO[L,5-ALPHA]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | THE UNIVERSITY OF SYDNEY (AU) | 2012-07-26 | — | — | US | disclosed |
| US-20090311176-A1 | 2-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) | THE UNIVERSITY OF SYDNEY (AU) | 2009-12-17 | — | — | US | disclosed |
| US-20090311176-A1 | 2-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) | THE UNIVERSITY OF SYDNEY (AU) | 2009-12-17 | — | — | US | disclosed |
| US-20090311176-A1 | 2-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) | THE UNIVERSITY OF SYDNEY (AU) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134362-A1 | 2-ARYLPYRAZOLO[L,5-α]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | THE UNIVERSITY OF SYDNEY (AU) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311176-A1 | 2-Arylpyrazolo[L,5-Alpha] Pyrimidin-3-YL Acetamide Derivatives as Ligands for Translocator Protein (18 Kda) | TSPO, SLC18A2, TMEM14C | HTT 584/4885MAPK10 2619/4885SMN1; SMN2 1827/4885 |
| US-20120189548-A1 | 2-ARYLPYRAZOLO[L,5-ALPHA]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA) | TSPO, TMEM14C, SLC18A2 | HTT 615/4885MAPK10 2601/4885SMN1; SMN2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.